Summit Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Summit Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 96% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 95% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-586.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 96% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +13%In 3 years sales changed by -100% while total assets changed by +13%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-95.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 82% of Healthcare companies in United States.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Lower than 56% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 94% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 95% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Summit Therapeutics Inc. made a loss over the last year. Summit Therapeutics Inc. owes $0.16 for every $1 it owns. Summit Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSummit Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
19.69The share price is 19.69 times Summit Therapeutics Inc.'s book value per share, higher than 94% of Healthcare companies in United States.
Market cap
$12.4 BThe total market value of all of Summit Therapeutics Inc.'s shares at today's price (share price × number of shares), larger than 92% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$630 MWhat Summit Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.79Net worth divided by the number of shares. The share price of $15.55 is 19.7 times this, which is the P/B above.
Return on equity (ROE)
-192.5%Summit Therapeutics Inc. lost 192.5% of its shareholders' money over the last year, lower than 84% of Healthcare companies in United States.
Owes vs Owns
0.16×Summit Therapeutics Inc. owes $0.16 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Dividend yield
NoneSummit Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossSummit Therapeutics Inc. made a loss in each of the last two years.
Cash vs debt
Net cashSummit Therapeutics Inc. held $693 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Summit Therapeutics Inc.: $12.4 B ÷ $630 M (30 Jun 2026) = 19.7.
What is Summit Therapeutics Inc.'s return on equity?
Summit Therapeutics Inc. lost 192.5% of its shareholders' money over the last year, lower than 84% of Healthcare companies in United States.
How much does Summit Therapeutics Inc. owe compared with what it owns?
Summit Therapeutics Inc. owes $0.16 for every $1 it owns (low), lower than 78% of Healthcare companies in United States.
Does Summit Therapeutics Inc. pay a dividend?
No. Summit Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.